SignaBlok presented proof-of-concept animal data on development of novel MRI contrast agent for diagnostic imaging of atherosclerosis at the 2014 Joint Annual Meeting ISMRM-ESMRMB

SignaBlok > News

SignaBlok > News

SignaBlok presented proof-of-concept animal data on development of novel MRI contrast agent for diagnostic imaging of atherosclerosis at the 2014 Joint Annual Meeting ISMRM-ESMRMB

SignaBlok presented proof-of-concept animal data on development of a novel ligand-independent inhibitor of TREM-1 for treatment of sepsis and lung cancer at the 2014 AACR Annual Meeting

SignaBlok presented TREM-1 program in inflammation and cancer at the 2014 Inflammation, Infection and Cancer Keystone Symposium

Inhibition of TREM-2 markedly suppresses joint inflammation and damage in experimental arthritis

Sigalov AB. Int J Mol Sci. 2022

Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis

Shen ZT and Sigalov AB. J Cell Mol Med. 2017

Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages

Sigalov AB. Contrast Media Mol Imaging. 2014

SignaBlok awarded NCI / NIH SBIR Phase I grant to test new approach to lung cancer treatment

SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new nanotechnology for diagnostic imaging of atherosclerosis

SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice

Shen ZT and Sigalov AB. Sci Rep. 2016

SignaBlok awarded DARPA contract to support new technology to combat sepsis